281 related articles for article (PubMed ID: 25562438)
1. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
[TBL] [Abstract][Full Text] [Related]
2. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.
Hashizume H; Falcón BL; Kuroda T; Baluk P; Coxon A; Yu D; Bready JV; Oliner JD; McDonald DM
Cancer Res; 2010 Mar; 70(6):2213-23. PubMed ID: 20197469
[TBL] [Abstract][Full Text] [Related]
3. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo.
Suzuki R; Yamamoto H; Ngan CY; Ohtsuka M; Kitani K; Uemura M; Nishimura J; Takemasa I; Mizushima T; Sekimoto M; Minamoto T; Doki Y; Mori M
Int J Oncol; 2013 Nov; 43(5):1447-55. PubMed ID: 23982687
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
6. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
7. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
9. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
11. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
13. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
Gallagher DC; Bhatt RS; Parikh SM; Patel P; Seery V; McDermott DF; Atkins MB; Sukhatme VP
Clin Cancer Res; 2007 Apr; 13(7):2115-20. PubMed ID: 17404094
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Sweep FC; Geurts-Moespot A; Engelhardt MS; van der Graaf WT; Oyen WJ; van Laarhoven HW
Mol Pharm; 2014 Nov; 11(11):4249-57. PubMed ID: 25294389
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.
Mizobe T; Ogata Y; Murakami H; Akagi Y; Ishibashi N; Mori S; Sasatomi T; Shirouzu K
Oncol Rep; 2008 Sep; 20(3):517-23. PubMed ID: 18695900
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
18. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
19. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.
Huang H; Lai JY; Do J; Liu D; Li L; Del Rosario J; Doppalapudi VR; Pirie-Shepherd S; Levin N; Bradshaw C; Woodnutt G; Lappe R; Bhat A
Clin Cancer Res; 2011 Mar; 17(5):1001-11. PubMed ID: 21233403
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Jin K; Lan H; Xie B; He K; Xu Z; Li G; Han N; Teng L; Cao F
Cancer Biol Ther; 2012 Jul; 13(9):737-44. PubMed ID: 22617773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
